ARS Pharmaceuticals Inc (NASDAQ: SPRY) is 66.61% higher on its value in year-to-date trading and has touched a low of $2.55 and a high of $9.65 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SPRY stock was last observed hovering at around $8.65 in the last trading session, with the day’s gains setting it 0.48%.
Currently trading at $9.13, the stock is 3.99% and 21.65% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.29 million and changing 5.55% at the moment leaves the stock 50.41% off its SMA200. SPRY registered 14.27% gain for a year compared to 6-month gain of 130.56%. The firm has a 50-day simple moving average (SMA 50) of $21.77k and a 200-day simple moving average (SMA200) of -$9.67.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 9.34% loss in the last 1 month and extending the period to 3 months gives it a 79.02%, and is 0.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.30% over the week and 5.92% over the month.
ARS Pharmaceuticals Inc (SPRY) has around 26 employees, a market worth around $881.05M and $0.03M in sales. Profit margin for the company is -181216.67%. Distance from 52-week low is 258.04% and -5.39% from its 52-week high. The company has generated returns on investments over the last 12 months (-23.56%).
ARS Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.15.The EPS is expected to shrink by -17.19% this year, but quarterly earnings will post 18,366.70% year-over-year.
ARS Pharmaceuticals Inc (SPRY) Top Institutional Holders
146 institutions hold shares in ARS Pharmaceuticals Inc (SPRY), with institutional investors hold 93.99% of the company’s shares. The shares outstanding are 96.41M, and float is at 41.68M with Short Float at 11.06%. Institutions hold 68.09% of the Float.
The top institutional shareholder in the company is Deerfield Management Company, L.P. (Series C) with over 11.08 million shares valued at $101.14 million. The investor’s holdings represent 11.48% of the SPRY Shares outstanding. As of Dec 30, 2023, the second largest holder is RA Capital Management, L.P. with 9.46 million shares valued at $86.37 million to account for 9.80% of the shares outstanding. The other top investors are Orbimed Advisors LLC. which holds 9.24 million shares representing 9.58% and valued at over $84.37 million, while Franklin Resources, Inc. holds 4.25% of the shares totaling 4.1 million with a market value of $37.42 million.
ARS Pharmaceuticals Inc (SPRY) Insider Activity
The most recent transaction is an insider sale by Tanimoto Sarina,the company’sCHIEF MEDICAL OFFICER. SEC filings show that Tanimoto Sarina sold 472 shares of the company’s common stock on Mar 21 ’24 at a price of $9.00 per share for a total of $4248.0. Following the sale, the insider now owns 1.75 million shares.
ARS Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 21 ’24 that Lowenthal Richard E (PRESIDENT AND CEO) sold a total of 472 shares of the company’s common stock. The trade occurred on Mar 21 ’24 and was made at $9.00 per share for $4248.0. Following the transaction, the insider now directly holds 1.75 million shares of the SPRY stock.
Still, SEC filings show that on Mar 19 ’24, Lowenthal Richard E (PRESIDENT AND CEO) disposed off 1,918 shares at an average price of $9.03 for $17324.0. The insider now directly holds 1,746,471 shares of ARS Pharmaceuticals Inc (SPRY).
